From NPR.

Federal regulators have approved a pill version of the popular weight loss drug Wegovy, which is currently only available as an injection. The pills could hit the market by early next year.

Meanwhile, injectable GLP-1 weight loss drugs have transformed obesity care, but they don’t work for everyone.

Roughly half of those who take GLP1s lose 15% or more of their bodyweight, but a minority — about one in six — lose very little. Doctors specializing in obesity care say this is because dozens of factors can contribute to a person’s obesity, and the new class of popular medicines may not address a person’s particular biology.

In few years, though, experts expect genetic and other tests to make it easier to personalize treatments to individual needs.